Letter of Medical Necessity for Rituximab
Pranzatelli MR, Tate ED, Travelstead AL, etal. Rituximab (anti-CD20) adjunctive therapy for opsoclonus-myoclonus syndrome. JPediatr Hematol Oncol 28 (9); 585-593, 2006.
Zaja F, Iacona I, Masolini P, et al. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia. Haematologica 87:189-195, 2002.
Specks U, Fervenza FC, McDonald TJ, Hogan MC. Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. Arthritis Rheum 44:2836-40, 2001.
Zaja F, Russo D, Fuga G, et al. Rituximab in a case of cold agglutinin disease. Br J Haematol 115:232-233, 2001.
Quartier P, Brethon B, Philippet P, et al. Treatment of Childhood autoimmune haemolytic anaemia with rituximab. Lancet 358:1511-3, 2001.
Stasi R, Pagano A, Stipa E, Amadori S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood. 98:952-7, 2001.
Faurschou M, Hasselbalch HC, Nielsen OJ. Sustained remission of platelet counts following monoclonal anti-CD20 antibody therapy in two cases of idiopathic autoimmune thrombocytopenia and neutropenia. Eur J Haematol 66:408-11, 2001.
Heizmann M, Itin P, Wernli M, et al. Successful treatment of paraneoplastic pemphigus in follicular NHL with rituximab: report of a case and review of treatment for paraneoplastic phemigus in NHL and CLL. Am J Hematol 66:142-4, 2001.
Zecca M, De Stefano P, Nobili B, Locatelli F. Anti-CD20 monoclonal antibody
for the treatment of severe, immune-mediated, pure red cell aplasia and hemolytic
anemia. Blood 97:3995-7, 2001.
|Return to Previous Menu|